Medscape: No Benefit in Stable IBD, Kiniksa Q2 (ARCALYST +55% YoY), Medicare Bridge 27 Days In (Reprint)

IBD-GLP-1 emulated RCT: no benefit. AIDS 2026 Day 2 in Rio. Medicare GLP-1 Bridge update. Kiniksa Q2: ARCALYST +55% YoY. Post-PCAC BioPharma Dive editorial.

Editor's Note

Tuesday's digest is anchored by two clinical-and-payer stories on GLP-1 receptor agonists that complicate the class's uniformly positive narrative. First, a Medscape-published emulated randomized trial analysis using 2018-2023 US claims data found that adults with stable inflammatory bowel disease and comorbid obesity or diabetes who initiated semaglutide or tirzepatide did not have a lower risk of IBD relapse or improved safety outcomes versus non-initiators. This finding challenges the anti-inflammatory hypothesis advanced in some preclinical literature and counters the informal assumption that GLP-1 receptor agonists may protect against IBD flares in obese or diabetic populations. Second, the Medicare GLP-1 Bridge Program is 27 days into its July 1 launch, which provides Wegovy, Zepbound KwikPen, and Foundayo at a $50 capped monthly copay for approximately 3.8 million eligible Medicare Part D beneficiaries through December 31, 2027. Actual enrollment data has not yet been released by CMS. The 26th International AIDS Conference (AIDS 2026) continues Day 2 in Rio de Janeiro with WHO's integrated primary health care workshop on sustaining HIV, TB, viral hepatitis, and STI services for key populations, plus EATG poster sessions and CHAI cost-effectiveness analyses. In the non-GLP-1 peptide industry, Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported Q2 2026 results Tuesday, with ARCALYST (rilonacept, IL-1α/IL-1β trap fusion protein for recurrent pericarditis) generating $243.6 million in net product revenue (+55% YoY), plus positive Phase 2 data on KPL-387. Additionally, BioPharma Dive published a post-PCAC editorial framing the July 23-24 vote as broader use of six of seven peptides despite the substantive evidence gap.

1

Medscape Publishes Analysis of Emulated Randomized Trial on Tuesday, July 28, 2026, Using 2018-2023 US Insurance Claims Data: Adults With Stable Inflammatory Bowel Disease (IBD) and Comorbid Obesity or Diabetes Who Initiated Semaglutide or Tirzepatide Did Not Experience a Lower Risk of IBD Relapse or Improved Safety Event Rates Compared to Non-Initiators. Both Cohort 1 (Patients on 5-Aminosalicylates or No IBD-Specific Therapy) and Cohort 2 (Patients on Immunomodulators or Advanced Therapies) Reported No Benefit From GLP-1 Receptor Agonist Initiation on IBD Clinical Outcomes

Medscape published an emulated randomized trial analysis on Tuesday, July 28, 2026, using US insurance claims data from 2018–2023 to determine whether patients with stable inflammatory bowel disease (IBD) and comorbid obesity or diabetes benefit from initiating GLP-1 receptor agonist therapy in addition to their ongoing IBD treatment. The researchers employed a target trial emulation design comparing patients who started semaglutide or tirzepatide with those who did not. Two cohorts were analyzed: Cohort 1 included patients on 5-aminosalicylates or no IBD-related therapy; Cohort 2 included patients on immunomodulators and/or advanced therapies (biologics or small molecules). Neither cohort showed a reduced risk of IBD relapse or improved safety event rates among GLP-1 initiators. These findings challenge the anti-inflammatory hypothesis proposed in preclinical GLP-1 receptor agonist literature (based on animal-model reductions in gut inflammation) and contradict the informal clinical assumption that IBD patients with obesity or diabetes may gain anti-inflammatory benefits from starting GLP-1 therapy. Clinical takeaway: Prescribers should not initiate GLP-1 receptor agonist therapy in stable IBD patients for the purpose of improving IBD outcomes. Initiating GLP-1 for obesity or diabetes in this population remains appropriate when the metabolic indication independently justifies it.

2

26th International AIDS Conference (AIDS 2026) Day 2, Tuesday, July 28, 2026 in Rio de Janeiro Includes World Health Organization (WHO) Interactive Workshop 14:30-16:30 BRT in Room 101C on Practical Approaches to Sustaining HIV, Tuberculosis (TB), Viral Hepatitis, and Sexually Transmitted Infection (STI) Services for Key Populations Through Integrated Primary Health Care, Plus European AIDS Treatment Group (EATG) Poster Sessions on the SCOPE, Belong, and RBDCOV Projects, and Clinton Health Access Initiative (CHAI) Cost-Effectiveness Presentation on Dual HIV/Syphilis and Triplex HIV/Syphilis/HBV Rapid Diagnostic Testing Among Pregnant Women in Kenya and South Africa (15:27-15:35 BRT)

The 26th International AIDS Conference (AIDS 2026) Day 2 continues Tuesday, July 28, 2026, at Riocentro in Rio de Janeiro, Brazil. Key Tuesday programming includes: the World Health Organization (WHO) interactive workshop in Room 101C from 14:30-16:30 BRT on practical approaches to sustaining HIV, tuberculosis (TB), viral hepatitis, and sexually transmitted infection (STI) services for key populations through integrated primary health care (particularly timely following the UNAIDS 'United to End AIDS' report Monday documenting 2025 HIV funding cuts); the European AIDS Treatment Group (EATG) poster sessions Tuesday and Wednesday on the SCOPE, Belong, and RBDCOV research projects; the Clinton Health Access Initiative (CHAI) cost-effectiveness presentation on dual HIV/syphilis and triplex HIV/syphilis/HBV rapid diagnostic testing among pregnant women in Kenya and South Africa (15:27-15:35 BRT); and the ViiV Healthcare peer-support-in-HIV-care session from 12:00-13:00 BRT. All abstracts (oral, poster, e-poster, and late-breaker) became available on-demand Monday, July 27, at 14:00 BRT for registered delegates, with on-demand session recordings available 4-12 hours after they take place. The main peptide-adjacent industry late-breaker (Gilead-Merck ISLEND-1 and ISLEND-2 detailed data) is scheduled for Wednesday, July 29.

3

Medicare GLP-1 Bridge Program Reaches 27 Days Since the July 1, 2026 CMS Pilot Launch, Offering All Formulations of Wegovy (Semaglutide, Novo Nordisk), the KwikPen Formulation of Zepbound (Tirzepatide, Eli Lilly), and All Formulations of Foundayo (Orforglipron, Eli Lilly) to Eligible Medicare Part D Beneficiaries at a Capped $50 Monthly Copay Through December 31, 2027. KFF Analysis Estimates Approximately 3.8 Million Medicare Beneficiaries Meet the Clinical Eligibility Criteria for the Program (~8% of the 47.5 Million Part D Enrollees Nationally), Although CMS Has Not Yet Released Actual Enrollment Data From the First Program Month

The Centers for Medicare & Medicaid Services (CMS) Medicare GLP-1 Bridge Program is 27 days into its July 1, 2026 pilot launch. The program provides eligible Medicare Part D beneficiaries access to specified GLP-1 receptor agonist products at a capped $50 monthly out-of-pocket cost through December 31, 2027. Covered products include all formulations of Wegovy (semaglutide, Novo Nordisk), the KwikPen formulation of Zepbound (tirzepatide, Eli Lilly), and all formulations of Foundayo (orforglipron, Eli Lilly). The program was established under a Most-Favored-Nation (MFN) pricing agreement announced by the Trump administration in Q1 2026, which combines manufacturer discounts with a fixed patient copay. A KFF (Kaiser Family Foundation) analysis estimates that approximately 3.8 million Medicare beneficiaries meet the program's clinical eligibility criteria—obesity with BMI ≥ 30 kg/m² and specific cardiovascular or metabolic comorbidities—representing about 8% of the 47.5 million Part D enrollees nationwide. CMS has not yet released actual enrollment data from the first month of the program. The pilot's real-world utilization patterns, adherence rates, and spending trends will determine whether it extends beyond December 31, 2027 or becomes a permanent Medicare Part D obesity benefit.

4

Industry

Kiniksa Pharmaceuticals (NASDAQ: KNSA) Reports Q2 2026 Financial Results and Recent Portfolio Execution on Tuesday, July 28, 2026. ARCALYST® (rilonacept), an IL-1α and IL-1β Cytokine Trap Fusion Protein, generated net product revenue of $5 million (+55% year-over-year) for the approved recurrent pericarditis indication. The company also reported positive Phase 2 data from the KPL-387 program demonstrating rapid and sustained reductions in pain and inflammation at the 300 mg once-monthly subcutaneous injection dose. Kiniksa hosted an 8:30 AM Eastern Time conference call to discuss Q2 financial performance and portfolio pipeline advancement.

Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported Q2 2026 financial results on Tuesday, July 28, 2026, with ARCALYST (rilonacept, an IL-1α and IL-1β cytokine trap fusion protein) net product revenue of $243.6 million, representing +55% year-over-year growth. ARCALYST is FDA-approved to reduce the risk of recurrent pericarditis in patients 12 years of age and older and serves as Kiniksa's primary commercial franchise. The Q2 revenue trajectory reflects continued adoption by cardiovascular specialists of rilonacept as a maintenance therapy alternative to colchicine-plus-corticosteroid regimens for patients with recurrent pericarditis. Separately, Kiniksa reported Phase 2 data from the KPL-387 program (an investigational IL-1 receptor antagonist monoclonal antibody), demonstrating rapid and sustained reductions in pain and inflammation at the 300 mg subcutaneous dose administered once monthly. The company hosted a conference call and webcast at 8:30 AM Eastern Time on Tuesday, July 28, to discuss Q2 financial performance and portfolio pipeline advancement, including next-step development of KPL-387, commercial expansion of ARCALYST, and additional pipeline candidates. Kiniksa Pharmaceuticals is one of the peptide-adjacent biotech companies focused on inhibiting the IL-1 pathway through both antibody and fusion-protein modalities.

5

BioPharma Dive Publishes Post-PCAC Editorial on Monday, July 27, 2026: Frames the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) Two-Day Session as Panel Endorsement of Broader Use of Six of Seven Peptides Despite Lack of Substantive Human Efficacy or Safety Evidence Supporting Their Benefits. Capital Now Shifting Toward Peptide-Adjacent Companies With Documented FDA Regulatory Engagement, Well-Defined Clinical Development Strategies, and Scalable Manufacturing Infrastructure Rather Than the Compounding-Pharmacy Gray Market That Has Historically Dominated Distribution

BioPharma Dive published a post-PCAC editorial on Monday, July 27, 2026, framing the outcome of the FDA Pharmacy Compounding Advisory Committee (PCAC) two-day session held July 23-24 as an advisory endorsement for broader use of six of seven peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon), despite the panel's rejection of substantive human efficacy or safety evidence. The editorial characterizes the vote as a significant departure from the FDA's traditional science-based standards for compounding substance eligibility and highlights the major shift in venture capital and pharmaceutical industry positioning that has followed. Capital is now flowing toward peptide-adjacent companies with documented FDA regulatory engagement (formal drug-development programs seeking NDA or BLA approval), well-defined clinical development strategies (Phase 1-3 registrational programs), and scalable manufacturing infrastructure (state-licensed compounding pharmacies with quality-control documentation, or FDA-registered 503B outsourcing facilities). The commentary contrasts this trajectory with the compounding-pharmacy gray market that has historically dominated peptide distribution (research-chemical suppliers, offshore pharmacies, and clinics operating outside FDA oversight). BioPharma Dive anchors its analysis on the July 23-24 PCAC vote as the catalyst for the current investment-cycle inflection and notes that Merck's July 16, 2026 FDA approval of LIPFENDRA (enlicitide, a macrocyclic peptide PCSK9 inhibitor) validates the legitimate drug-development pathway that peptide-industry commentary has positioned as an alternative to the compounding-first commercial strategy.